Trial Profile
A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Midazolam
- Indications Crohn's disease; Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Intestinal obstruction; Irritable bowel syndrome; Liver disorders; Rosacea; Skin and soft tissue infections; Traveller's diarrhoea
- Focus Pharmacokinetics
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 09 Mar 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2008 New trial record.